Libervant
Payments companies reported to CMS as associated with Libervant. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Libervant, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Libervant
These are the largest totals companies reported as associated with Libervant. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Gary Slatko | New York, NY | Internal Medicine | $217,816.67 |
| Matthew Greenhawt | Aurora, CO | Pediatric Allergy/Immunology | $35,109.22 |
| David Golden | Baltimore, MD | Allergy | $30,574.01 |
| Jay Lieberman | Memphis, TN | Allergy & Immunology | $18,520.95 |
| William Calhoun | Galveston, TX | Pulmonary Disease | $13,426.06 |
| Lydia Gilbert-Mcclain | Bethesda, MD | Critical Care Medicine (Internal Medicine) | $12,908.00 |
| Mark Ballow | Tampa, FL | Pediatric Allergy/Immunology | $8,977.69 |
| Sushama Scalera | Salem, MA | Emergency Medicine | $6,100.00 |
| Thomas Atkinson | Birmingham, AL | Allergy & Immunology | $6,097.27 |
| John Oppenheimer | Sag Harbor, NY | Internal Medicine | $6,000.00 |
Prescribed Libervant?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.